Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1892)	4/29/2016 12:58:37 AM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

PR, it has always puzzled me why an outfit like Takeda, obviously a Japanese pharma, got the license to the UK. Equally puzzling is why Takeda didn't get or press hard for a license for other EU countries...it never seemed to me worth it to license only one country. And why didn't Takeda seek the license for Japan? Regardless, I agree with you that if Vitaros was flying off the shelves in the UK as Takeda would have liked, Takeda would have kept it. However, I really wonder if reimbursement is that big a deal. After all, the issue here is the ability to have sex for crying out loud. And there are plenty of men out there for whom the cost of Vitaros is less than the cost of a Starbuck's habit or a tobacco habit. Quite frankly, I would not have been surprised to see the termination of the agreement with Sandoz in light of all of its problems. Takeda is a surprise. Maybe the silver lining is that Ferring will get its feet wet marketing Vitaros in preparation for marketing in Latin America. Just rambling...

To: phoenix_rising who wrote (1892)	4/29/2016 5:55:34 AM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

Another point on the Ferring deal, Takeda was to provide $36.6M in sales milestones for the UK. Under the revised agreement with Ferring, the latter will provide $16M in regulatory and sales milestones for the Territory. The Territory includes Latin America (and certain Caribbean countries) and now the UK. But, $16M in sales milestones is what Ferring already agreed to for Latin America. So it looks to me like the company lost all the future sales milestones for the UK. Those sales milestones continue to be elusive and now dwindling. However, if Ferring is aggressive in its Territory, I would gladly pass on the sales milestones at this point.